Laura Dillon, PhD, FACMG

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission medrxiv.org/content/10.64898…

Important talk at #ASH25 by @JesseTettero on AML MRD as a surrogate endpoint (Session 619 - Valencia Room W415A).

Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25 #ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML meetings-api.hematology.org/…

#Tandem25 I'll be talking today (10.30am Ballroom B, 4th flr) about the Pre-MEASURE AML MRD project which used CIBMTR Clinical Data and Biospecimens. The current issue of nature.com/BMT focuses on this research, and is dedicated to Dr. Kristin Page our @CIBMTR colleague and co-author. nature.com/articles/s41409-0… . . If you have not yet, please consider donating here: gofundme.com/f/dwkhq-support…

Delighted to have Dr. Dillon join us at the Virginia Tech @FralinBiomed Cancer Research Center in DC as Research Associate Professor. The Pre-MEASURE team is back together(!) as we, with help from others, dive into the MEASURE protocol and continue our @FNIH_Org work on AML MRD

TP53 mutation screening for patients at risk of myeloid malignancy | Leukemia ⁦@Devdeep07⁩ ⁦⁦⁦@LauraWDillon⁩ nature.com/articles/s41375-0…

Secondary primary malignancies are increasingly recognized as a risk of cellular therapies (esp. MDS/AML, also after chemotx/radiotx) - we were asked to bring up a ultra-deep NGS assay for DISCOVERY of TP53 mutations for screening prior to treatment medrxiv.org/content/10.1101/…

Bottom lines: There does appear to be an association between level of FLT3-ITD persistence and clinical outcome (first time this has been definitively shown for AML MRD as far as I know). Levis and colleagues have found the same thing (they have an oral presentation later today)

I encourage you to listen to the recorded poster presentation by @LauraWDillon (who is unable to attend ASH in person this year - due to another project she is working on)

Cleveland clinic medical student ⁦@ClevelandClinic⁩ ⁦@hegdepranay1⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦@NIH⁩ ⁦@CIBMTR⁩

She crushed it! First major international talk for ⁦@GegeGui0⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦@CIBMTR⁩ ⁦@ASH_hematology⁩

Come listen (and support) Gege as she gives her first talk at an international hematology meeting! If we are serious about making things better for patients with blood cancer we need to encourage best and brightest students from other disciplines to work on our hardest problems

So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student ⁦@GegeGui0⁩ (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student ⁦⁦@hegdepranay1⁩ presenting TKD MRD poster tomorrow (Sun).

Proud of @GegeGui0 & @hegdepranay1 for their @ASH_hematology abstract awards for work on the next stages of #PreMEASURE AML MRD project. Part 1 showed persistent FLT3-ITD +/or NPM1mut in CR1 blood before alloHCT assoc with ⬆relapse & death. What about FLT3-TKD, IDH1m, and IDH2m?

The best and the brightest from medical, dental, and vet schools around the US come to @NIH for a year during training to do research. They work hard and do well by doing good. Was an honor to host Pranay Hegde - no surprise to see him win this national award for his work with us